**Supporting information**

**Table1. Tremor scores for patients with PIGD and non-PIGD subtypes**

|  |  |  |  |
| --- | --- | --- | --- |
| Subjects | | Tremor score | |
| P006 | | 2 | |
| P015 | | 2 | |
| P017 | | 0 | |
| P021 | | 1 | |
| P025 | | 0 | |
| P036 | | 0 | |
| P044 | | 0 | |
| P053 | | 0 | |
| P057 | | 2 | |
| P059 | | 0 | |
| P065 | | 0 | |
| P072 | | 2 | |
| NP007 | | 3 | |
| NP012 | | 23 | |
| NP024 | | 3 | |
| NP028 | | 2 | |
| NP032 | | 13 | |
| NP033 | | 3 | |
| NP038 | | 20 | |
| NP040 | | 9 | |
| NP041 | | 14 | |
| NP061 | | 4 | |
| NP068 | | 15 | |
| NP071 | | 12 | |
| PIGD | **non-PIGD** | | **T (P value)** |
| 0.75 ± 0.96 | 10.1 ± 7.2 | | -4.45 (**0.001\***) |

Bold value and “\*” means a statistical difference between the PIGD and non-PIGD subtypes with the statistical threshold set at P < 0.05. P = PIGD; NP = non-PIGD

**Table2. Daily levodopa equivalent dose (LED) for sixteen treated patients**

|  |  |  |  |
| --- | --- | --- | --- |
| Subjects | Drug | | Daily LED (mg) |
| P006 | Piribedil | | 150.0 |
| P017 | Controlled release L-dopa + Selegiline (oral) + Amantadine | | 400.0 |
| P025 | Amantadine | | 200.0 |
| P036 | Immediate release L-dopa + Piribedil | | 750.0 |
| P044 | Immediate release L-dopa + Amantadine | | 500.0 |
| P053 | Immediate release L-dopa + Selegiline (oral) + Amantadine + Pramipexole | | 1000.0 |
| P057 | Immediate release L-dopa | | 600.0 |
| NP012 | Immediate release L-dopa + Entacapone + Controlled release L-dopa + Piribedil | | 699.0 |
| NP024 | Controlled release L-dopa + Pramipexole | | 425.0 |
| NP032 | Immediate release L-dopa + Ropinirole | | 280.0 |
| NP033 | Immediate release L-dopa + Piribedil + Amantadine | | 958.3 |
| NP038 | Immediate release L-dopa + Amantadine | | 450.0 |
| NP040 | Amantadine | | 300.0 |
| NP041 | Immediate release L-dopa + Amantadine + Pramipexole + Controlled release L-dopa | | 837.5 |
| NP061 | Controlled release L-dopa + Amantadine + Piribedil | | 450.0 |
| NP068 | Selegiline (oral) + Piribedil | | 100.0 |
| Mean | PIGD | non-PIGD | T (P value) |
| 300.0 ± 345.7 | 375.0 ± 328.2 | -0.54 (0.595) |

P = PIGD; NP = non-PIGD

**Table3. Fazekas scores for patients with PIGD and non-PIGD subtypes**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Subjects | Fazekas score | | | | | |  |
| Operator 1 Operator 2 | | | | | | Average |
| P006 | 2 | | | 2 | | | 2 |
| P015 | 1 | | | 1 | | | 1 |
| P017 | 2 | | | 2 | | | 2 |
| P021 | 5 | | | 4 | | | 4.5 |
| P025 | 2 | | | 2 | | | 2 |
| P036 | 1 | | | 1 | | | 1 |
| P044 | 2 | | | 2 | | | 2 |
| P053 | 2 | | | 2 | | | 2 |
| P057 | 1 | | | 1 | | | 1 |
| P059 | 0 | | | 1 | | | 0.5 |
| P065 | 1 | | | 0 | | | 0.5 |
| P072 | 2 | | | 2 | | | 2 |
| NP007 | 2 | | | 2 | | | 2 |
| NP012 | 0 | | | 1 | | | 0.5 |
| NP024 | 2 | | | 2 | | | 2 |
| NP028 | 2 | | | 2 | | | 2 |
| NP032 | 2 | | | 2 | | | 2 |
| NP033 | 0 | | | 0 | | | 0 |
| NP038 | 2 | | | 2 | | | 2 |
| NP040 | 1 | | | 2 | | | 1.5 |
| NP041 | 2 | | | 2 | | | 2 |
| NP061 | 2 | | | 2 | | | 2 |
| NP068 | 2 | | | 2 | | | 2 |
| NP071 | 3 | | | 3 | | | 3 |
| PIGD | | **non-PIGD** | | | **T (P value)** | | |
| 1.7 ± 1.1 | | | 1.7 ± 0.8 | | | -0.11(0.913) | |

P = PIGD; NP = non-PIGD